"Getting breakthroughs out of the lab
and into the world."

Twelve years taking precision oncology diagnostics from concept to market — joined ANGLE's founding team and grew from bench scientist to product and strategy lead.

12yrs
in precision
oncology dx
150+
deployments
+ CLIA lab
−33%
service costs
via VOC program insights
FDA
De Novo
+ MDR cleared
concept→market

Experience Snapshot

ANGLE plc

2012 – 2023
Publicly traded company that ran like a startup (~300 staff at peak); developer of the Parsortix circulating tumor cell platform.

Foundational team that took Parsortix from concept through FDA De Novo + MDR clearance to commercial launch, 150+ deployments, and a CLIA lab.

Ran the voice-of-customer and beta program across 80+ sites, cutting development-cycle time 21%, service visits 19%, and service costs 33%.

Independent Product Strategy

2024 – Present

Authored a white paper on why precision diagnostics stall before clinical adoption — with a commercialization playbook and frameworks for cross-functional product alignment.

The Library — PKM Community

2024 – Present
~350-member paid community for knowledge workers building systems to capture and reuse what they know.

As fractional Community Manager, partnered with the founder to grow paid membership +230% and built automation into the onboarding system for new members.

Target Companies

BillionToOne Bio-Techne Bruker Delfi Diagnostics Foundation Medicine / Roche Freenome GRAIL Guardant Health Natera Personalis Proscia Quanterix Tempus Veracyte 10x Genomics
Make an introduction

Know someone working at my targets, or a role that'd be a fit? A quick intro or forward means a lot.  Reach me at chris@cwagner.co.

This is a one-page snapshot, not my full résumé. Please connect if you'd like the complete version or to learn more.